MISSISSAUGA, ON, Sept. 30 /CNW/ - YM BioSciences Inc. (AMEX: YMI, TSX:
YM, AIM: YMBA), an oncology company that identifies, develops and
commercializes differentiated products for patients worldwide, today announced
that two of its licensees for nimotuzumab, Daiichi-Sankyo Co., Ltd. in Japan
and Kuhnil Pharmaceutical Co. in Korea, advise that they have commenced the
enrollment in an 80-patient Phase II randomized, open-label trial of
nimotuzumab (400mg weekly until progression) plus irinotecan (150mg/m(2)
biweekly until progression) compared to irinotecan alone in patients with
advanced or recurrent gastric cancer who are refractory to 5-FU-containing
regimens. Enrollment is expected to be completed in calendar 2009.
